Drug intelligence / Profile preview

HT125

Development stage
Preclinical
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration
Intravenous
01

Overview

HT125 is a novel delta-like ligand 3 (DLL3)-targeting cyclic peptide conjugate developed for integrated theranostic applications, including positron emission tomography (PET) imaging and targeted radionuclide therapy [EP-0040]. Developed by Hangzhou Healthytide Biotechnology and ShanghaiTech University, HT125 is a modified version of the DLL3-targeting monocyclic peptide MC339 [EP-0040]. When conjugated with chelators such as DOTA or NOTA, HT125 can be radiolabeled with diagnostic isotopes (such as fluorine-18 or gallium-68) for PET imaging, or therapeutic isotopes (such as lutetium-177 or actinium-225) for targeted radionuclide therapy [EP-0040]. In preclinical models of DLL3-overexpressing small cell lung cancer (SCLC) and neuroendocrine tumors, radiolabeled HT125 demonstrated high tumor uptake, favorable tumor-to-background contrast, prolonged tumor retention, and significant tumor growth inhibition [EP-0040].

Other names
177Lu-DOTA-HT12518F-AlF-NOTA-HT125225Ac-DOTA-HT12568Ga-DOTA-HT125DOTA-HT125DOTA-HT-125DOTA-HT 125NOTA-HT125NOTA-HT-125NOTA-HT 125
02

Identity

Drug type
Peptides
Modality
PeptidesAntibody-Based TherapeuticsAntibody-Radionuclide Conjugates
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
small-cell lung cancer (SCLC)PreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

07

Competitive landscape

Drugs on the same target
37
Drugs in the lead indication
432

Lead indication: small-cell lung cancer (SCLC)

Most advanced in the lead indication

  1. etoposideApproved
  2. methotrexateApproved
  3. topotecanApproved
  4. anlotinibPhase 4
  5. aprepitantPhase 4

Beyond the preview

Go deeper on HT125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HT125.

Work on HT125? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call